Navigation Links
Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Date:8/26/2010

t damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights;
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bioheart, Inc. Announces Additional Funding Support
2. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
3. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
4. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
5. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Tocagen ... updated interim data from Tocagen,s ongoing investigational studies ... Symposium of the American Association of Neurological Surgeons ... held May 1-2, 2015, in Washington, ... company held a meeting with FDA and continues ...
(Date:5/1/2015)... May 1, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... second tranche of a $40 million investment from Woodford ... first invested $25 million in NW Bio on November ... an agreement with the Company for a further $40 ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North American ... is the proud recipient of two Cisco® Partner Summit Country ... of the Year and Security Partner of the Year for ... taking place this week in Montreal . ... but two Cisco partner awards at this year,s conference," said ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... for the, hospital market, works anywhere ... Wash., June 16 Cardiac Science today,announced the ... product for the hospital market. Pyramis 6.2 centralizes,diagnostic ... within a,hospital network. Cardiac Science (Nasdaq: CSCX ...
... campaign to encourage early diagnosis of dementia ... and participation in clinical ... Power of the Internet to Transform Medical ... YouTube and The University of,California, San Francisco (UCSF) ...
... June 16 Cell Therapeutics, Inc.,(CTI) (Nasdaq and ... the,remaining balance, including accrued interest, of its 2008 ... through a cash payment of,approximately $11.0 million. The ... "Retiring this last piece of current debt ...
Cached Biology Technology:Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 2Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 3Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 4UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 2UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 3Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... to the expansion of protected area systems could ultimately ... to a new paper in the scientific journal ... CSIRO Climate Adaptation Flagship and The University of Queensland ... improve the performance of protected area systems by replacing ...
... Germany , June 30 SCM Microsystems, a business unit ... of solutions for secure access, secure identity and secure exchange, announced that ... to German citizens under the new electronic identification program managed by ... , , ...
... the Association for Molecular Pathology (AMP) presented comments at ... array-based cytogenetic tests. The FDA convened the meeting to ... had on how to evaluate the performance, interpret results ... number variation (CNV). AMP believes array-based cytogenetic ...
Cached Biology News:Conserving nature and dollars: Delivering cost-effective biodiversity protection 2SCM Microsystems to Supply Readers for German Electronic ID Program 2SCM Microsystems to Supply Readers for German Electronic ID Program 3AMP comments at FDA meeting on array-based tests 2